BridgeBio Pharma (BBIO) Revenue (2018 - 2026)
BridgeBio Pharma (BBIO) revenue from Sep 30, 2018 to Mar 31, 2026. The TTM BridgeBio Pharma (BBIO) revenue is $580M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Revenue
Quarterly Revenue
BridgeBio Pharma (BBIO) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +355.20% |
| 3 Years TTM | +95.36% |
| 5 Years TTM | +131.57% |
| All Time TTM | +60.54% |
Annual Revenue change of BridgeBio Pharma (BBIO)
| Year | Revenue | Change |
|---|---|---|
| 2026 | $195M | -61.26% |
| 2025 | $502M | +126.26% |
| 2024 | $222M | +2286.02% |
| 2023 | $9.30M | -88.02% |
| 2022 | $78M | +11.37% |
| 2021 | $70M | +745.09% |
| 2020 | $8.25M | -79.66% |
| 2019 | $41M | N/A |
| 2018 | $0 | N/A |
| 2017 | $0 | N/A |
Comparison BridgeBio Pharma (BBIO) five years revenue CAGR with competitors
BridgeBio Pharma (BBIO) five years revenue CAGR is 131.56%.